Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 35, Issue 9, 2017, Pages 544.e11-544.e23

  Skowron, Margaretha A ^a   Sathe, Anuja ^b   Romano, Andrea ^c   Hoffmann, Michèle J ^a   Schulz, Wolfgang A ^a   van Koeveringe, Gommert A ^d   Albers, Peter ^a   Nawroth, Roman ^b   Niegisch, Günter ^a  

^a Department of Orthopedic Surgery   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chicken chorioallantoic membrane (CAM) model; Cisplatin; HDAC inhibitors; Romidepsin; Urothelial carcinoma; Vorinostat

Indexed keywords

ALPHA TUBULIN; CISPLATIN; CYCLIN E; CYTOKERATIN 18; CYTOKERATIN 20; CYTOKERATIN 5; KI 67 ANTIGEN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; ROMIDEPSIN; UVOMORULIN; VIMENTIN; VORINOSTAT;

ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CELL DIFFERENTIATION; CHICKEN; CHORIOALLANTOIC MEMBRANE ASSAY; DRUG POTENTIATION; EMBRYO; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RT-112 CELL LINE; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING; ANIMAL; CHICK EMBRYO; CHORIOALLANTOIS; GENETIC TRANSFECTION; METABOLISM; PATHOLOGY; URINARY TRACT TUMOR;

ANIMALS; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; HUMANS; TRANSFECTION; UROLOGIC NEOPLASMS;

EID: 85019588704     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2017.05.003     Document Type: Article

References (41)

1. DeGraff, D.J., Robinson, V.L., Shah, J.B., Brandt, W.D., Sonpavde, G., Kang, Y., et al. Current preclinical models for the advancement of translational bladder cancer research. Mol Cancer Ther 12 (2013), 121–130.
2. Kobayashi, T., Owczarek, T.B., McKiernan, J.M., Abate-Shen, C., Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer 15 (2015), 42–54.
3. Earl, J., Rico, D., Carrillo-de-Santa-Pau, E., Rodriguez-Santiago, B., Mendez-Pertuz, M., Auer, H., et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics, 16, 2015, 403.
4. Ding, J., Xu, D., Pan, C., Ye, M., Kang, J., Bai, Q., et al. Current animal models of bladder cancer: awareness of translatability (review). Exp Ther Med 8 (2014), 691–699.
5. Vargas, A., Zeisser-Labouebe, M., Lange, N., Gurny, R., Delie, F., The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. Adv Drug Deliver Rev 59 (2007), 1162–1176.
6. Mast, J., Goddeeris, B.M., Development of immunocompetence of broiler chickens. Vet Immunol Immunop 70 (1999), 245–256.
7. Rahman, A., Haque, S., Aktar, M., Developmental stage and assessment of embryonic growth of Gallus gallus domesticus. Univ J Zool Rajshahi Univ 33 (2014), 09–18.
8. Dohle, D.S., Pasa, S.D., Gustmann, S., Laub, M., Wissler, J.H., Jennissen, H.P., et al. Chick ex ovo culture and ex ovo CAM assay: how it really works. J Vis Exp, 2009.
9. Murphy, J.B., Rous, P., The behaviour of chicken sarcoma implanted in the developing embryo. J Exp Med 15 (1912), 119–132.
10. Scanlon, C.S., Inglehart, R.C., D'Silva, N.J., Emerging value: the chick chorioallantoic membrane (CAM) model in oral carcinogenesis. Res J Carcinog Mutagen, S5, 2013, 005.
11. Florea, A.M., Büsselberg, D., Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3 (2011), 1351–1371.
12. Pinkerneil, M., Hoffmann, M.J., Deenen, R., Kohrer, K., Arent, T., Schulz, W.A., et al. Inhibition of Class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms. Mol Cancer Ther 15 (2016), 299–312.
13. Niegisch, G., Knievel, J., Koch, A., Hader, C., Fischer, U., Albers, P., et al. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol 31 (2013), 1770–1779.
14. Hoffmann, M.J., Koutsogiannouli, E., Skowron, M.A., Pinkerneil, M., Niegisch, G., Brandt, A., et al. The new immortalized uroepithelial cell line HBLAK contains defined genetic aberrations typical of early stage urothelial tumors. Bladder Cancer 2 (2016), 449–463.
15. Sathe, A., Guerth, F., Cronauer, M.V., Heck, M.M., Thalgott, M., Gschwend, J.E., et al. Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer 111 (2014), 2103–2113.
16. Kind, C., Development of circulating blood-volume of chick-embryo. Anat Embryol 147 (1975), 127–132.
17. Barnes, A.E., Jensen, W.N., Blood volume and red cell concentration in the normal chick embryo. Am J Physiol 197 (1959), 403–405.
18. Skowron, M.A., Niegisch, G., Fritz, G., Arent, T., van Roermund, J.G., Romano, A., et al. Phenotype plasticity rather than repopulation from CD90/CK14+cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. J Exp Clin Canc Res, 34, 2015, 144.
19. Pinkerneil, M., Hoffmann, M.J., Kohlhof, H., Schulz, W.A., Niegisch, G., Evaluation of the therapeutic potential of the novel isotype specific HDAC inhibitor 4SC-202 in urothelial carcinoma cell lines. Target Oncol 11 (2016), 783–798.
20. Kunzi-Rapp, K., Genze, F., Kufer, R., Reich, E., Hautmann, R.E., Gschwend, J.E., Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. J Urol 166 (2001), 1502–1507.
21. Lokman, N.A., Elder, A.S.F., Ricciardelli, C., Oehler, M.K., Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. Int J Mol Sci 13 (2012), 9959–9970.
22. Balke, M., Neumann, A., Kersting, C., Agelopoulos, K., Gebert, C., Gosheger, G., et al. Morphologic characterization of osteosarcoma growth on the chick chorioallantoic membrane. BMC Res Notes, 3, 2010, 58.
23. Sys, G.M., Lapeire, L., Stevens, N., Favoreel, H., Forsyth, R., Bracke, M., et al. The in ovo CAM-assay as a xenograft model for sarcoma. J Vis Exp, 77, 2013, e50522.
24. Taizi, M., Deutsch, V.R., Leitner, A., Ohana, A., Goldstein, R.S., A novel and rapid in vivo system for testing therapeutics on human leukemias. Exp Hematol 34 (2006), 1698–1708.
25. Shen, X., Han, Y., Xue, X., Li, W., Guo, X., Li, P., et al. Epidermal growth factor-like domain 7 promotes cell invasion and angiogenesis in pancreatic carcinoma. Biomed Pharmacother 77 (2016), 167–175.
26. Ribatti, D., Vacca, A., Roncali, L., Dammacco, F., The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int J Dev Biol 40 (1996), 1189–1197.
27. Nagaraju, G.P., Park, W., Wen, J., Mahaseth, H., Landry, J., Farris, A.B., et al. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3. Angiogenesis 16 (2013), 903–917.
28. Cimpean, A.M., Ribatti, D., Raica, M., The chick embryo chorioallantoic membrane as a model to study tumor metastasis. Angiogenesis 11 (2008), 311–319.
29. Deryugina, E.I., Quigley, J.P., Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol 130 (2008), 1119–1130.
30. Li, M., Pathak, R.R., Lopez-Rivera, E., Friedman, S.L., Aguirre-Ghiso, J.A., Sikora, A.G., The in ovo chick chorioallantoic membrane (CAM) assay as an efficient xenograft model of hepatocellular carcinoma. J Vis Exp, 104, 2015, e52411.
31. Strojnik, T., Kavalar, R., Barone, T.A., Plunkett, R.J., Experimental model and immunohistochemical comparison of U87 human glioblastoma cell xenografts on the chicken chorioallantoic membrane and in rat brains. Anticancer Res 30 (2010), 4851–4860.
32. Russell, P.J., Raghavan, D., Gregory, P., Philips, J., Wills, E.J., Jelbart, M., et al. Bladder cancer xenografts: a model of tumor cell heterogeneity., 46, 1986, 2035–2040.
33. Kim, M.S., Blake, M., Baek, J.H., Kohlhagen, G., Pommier, Y., Carrier, F., Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63 (2003), 7291–7300.
34. Sharma, N.L., Groselj, B., Hamdy, F.C., Kiltie, A.E., The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. BJU Int. 111 (2013), 537–542.
35. Soloway, M.S., Niell, H.B., Matheny, R.B., Blatnik, A., Systemic chemotherapy of murine bladder cancer. Urology 23 (1984), 129–134.
36. Hickey, D.P., Brausi, M., Blatnik, A.F., Soloway, M.S., Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer. Urology 30 (1987), 484–487.
37. Ozawa, A., Tanji, N., Kikugawa, T., Sasaki, T., Yanagihara, Y., Miura, N., et al. Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int 105 (2010), 1181–1186.
38. Canes, D., Chiang, G.J., Billmeyer, B.R., Austin, C.A., Kosakowski, M., Rieger-Christ, K.M., et al. Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo. Int J Cancer 113 (2005), 841–848.
39. Buckley, M.T., Yoon, J., Yee, H., Chiriboga, L., Liebes, L., Ara, G., et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med, 5, 2007, 49.
40. Kyriazis, A.A., Kyriazis, A.P., McCombs, W.B. 3rd, Peterson, W.D. Jr, Morphological, biological, and biochemical characteristics of human bladder transitional cell carcinomas grown in tissue culture and in nude mice. Cancer Res 44 (1984), 3997–4005.
41. Kyriazis, A.P., Kyriazis, A.A., Yagoda, A., Time dependence of the radiation-modifying effect of cis-diamminedichloroplatinum II (cisplatin, DDP) on human urothelial cancer grown in nude mice. Cancer Invest 4 (1986), 217–222.